Alentis Therapeutics is a clinical stage biotechnology company that focuses on developing breakthrough treatments for fibrotic diseases and associated cancers. Alentis is using its portfolio of unique monoclonal antibodies that are highly selective for exposed and non-junctional Claudin-1. Claudin-1 a previously unexploited target that plays a key role in the pathology of fibrosis across organs as well as solid tumors.
Alentis Therapeutics
We chose the private labs at Switzerland Innovation Park Basel Area’s Main Campus for their modern infrastructure and exceptional life science network. The purpose-built lab facilities and strong support framework have been great, enabling us to customize our operations, focus on groundbreaking research, and advance scientific discoveries."
Markus Meyer, COO of Alentis
